Mresvia mRNA RSV
Selected indexed studies
- The recent landscape of RSV vaccine research. (Ther Adv Vaccines Immunother, 2025) [PMID:39802673]
- Development, Current Status, and Remaining Challenges for Respiratory Syncytial Virus Vaccines. (Vaccines (Basel), 2025) [PMID:40006644]
- FDA Approves mRESVIA: Embracing the New Era of RSV Prevention With Advanced mRNA Technology. (Ann Pharmacother, 2025) [PMID:39654133]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- The recent landscape of RSV vaccine research. (2025) pubmed
- Development, Current Status, and Remaining Challenges for Respiratory Syncytial Virus Vaccines. (2025) pubmed
- Respiratory Syncytial Virus Prevention in the Adult Population: State of the Art. (2025) pubmed
- FDA Approves mRESVIA: Embracing the New Era of RSV Prevention With Advanced mRNA Technology. (2025) pubmed
- Post-marketing safety monitoring of RSV vaccines: A real-world study based on the Vaccine Adverse Event Reporting System (VAERS). (2025) pubmed
- Reply: FDA Approved mRESVIA: Embracing the New Era of RSV Prevention With Advanced mRNA Technology. (2025) pubmed
- A Review of Respiratory Syncytial Virus Vaccines in the Older Adult. (2025) pubmed
- Coadministration of mRNA-1345 RSV vaccine with high-dose quadrivalent influenza vaccine in adults aged 65 and older: An observer-blinded, placebo-controlled, randomized, phase 3 trial. (2026) pubmed
- Editorial: Surveillance of Seasonal Respiratory Syncytial Virus (RSV) Infection in Children and Vulnerable Adults Drives Vaccine Development and New Immunization Programs. (2025) pubmed
- Summary of the National Advisory Committee on Immunization (NACI) statement on the prevention of respiratory syncytial virus (RSV) in older adults. (2025) pubmed